Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.48 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.46 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27695978 | 0.76 | CDK2 (0.47) | ALDH1A1CDK2RXFP1NPC1RAB9A | |
| SCHEMBL28833452 | 0.73 | ALDH1A1 (0.50) | ALDH1A1CDK2RXFP1NUDT1KDM4E | |
| SCHEMBL30306357 | 0.73 | CYP1A2 (0.49) | PARP1CSNK1A1DYRK1BTYRO3ALDH1A1 | |
| SCHEMBL9728693 | 0.73 | CYP1A2 (0.49) | PARP1CSNK1A1DYRK1BTYRO3ALDH1A1 | |
| SCHEMBL4772912 | 0.72 | CSNK1A1 (0.50) | PARP1CSNK1A1DYRK1BTYRO3ALDH1A1 | |
| SCHEMBL29452971 | 0.72 | ALDH1A1 (0.63) | ALDH1A1CDK2RXFP1KDM4ECHEK1 | |
| SCHEMBL1721311 | 0.71 | ALDH1A1 (0.55) | PARP1ALDH1A1CDK2RXFP1KDM4E | |
| SCHEMBL680856 | 0.71 | CDK2 (0.55) | ALDH1A1CDK2RXFP1NPC1RAB9A | |
| Purine SCHEMBL1060498 | 0.71 | PARP1 (0.46) | PARP1CSNK1A1DYRK1BTYRO3ALDH1A1 | |
| SCHEMBL9639625 | 0.70 | ALDH1A1 (0.46) | PARP1ALDH1A1CDK2RXFP1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240122927-A1 | METHODS FOR TREATING HEMOLYTIC DISEASES AND SICKLE CELL DISEASE | PURDUE RESEARCH FOUNDATION | 2024-04-18 | — | — | US | claimed |
| US-20230128322-A1 | SYK KINASE INHIBITORS AS TREATMENT FOR MALARIA | PURDUE RESEARCH FOUNDATION | 2023-04-27 | — | — | US | claimed |
| US-20230018687-A1 | METHODS FOR TREATING HEMOLYTIC DISEASES AND SICKLE CELL DISEASE | PURDUE RESEARCH FOUNDATION | 2023-01-19 | — | — | US | claimed |
| US-20200345737-A1 | SYK KINASE INHIBITORS AS TREATMENT FOR MALARIA | PURDUE RESEARCH FOUNDATION | 2020-11-05 | — | — | US | claimed |
| US-20140309233-A1 | SYK KINASE INHIBITORS AS TREATMENT FOR MALARIA | HULOW, LLC (US) | 2014-10-16 | — | — | US | claimed |
| WO-2014100113-A2 | SYK KINASE INHIBITORS AS TREATMENT FOR MALARIA | HULOW, LLC (US) | 2014-06-26 | — | — | WO | claimed |
| US-8470357-B2 | Methods of treatment with Syk inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-06-25 | — | — | US | claimed |
| US-20120027834-A1 | METHODS OF TREATMENT WITH SYK INHIBITORS | Portola Phamaceuticals, Inc. (US) | 2012-02-02 | — | — | US | claimed |
| US-8057815-B2 | Methods of treatment with Syk inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | claimed |
| EP-1737386-A1 | METHODS OF TREATMENT WITH SYK INHIBITORS | Portola Pharmaceuticals, Inc. (US) | 2007-01-03 | — | — | EP | claimed |
| WO-2005102215-A1 | METHODS OF TREATMENT WITH SYK INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | WO | claimed |
| US-20050232969-A1 | Methods of treatment with Syk inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | US | claimed |
| US-20240122927-A1 | METHODS FOR TREATING HEMOLYTIC DISEASES AND SICKLE CELL DISEASE | PURDUE RESEARCH FOUNDATION | 2024-04-18 | — | — | US | disclosed |
| US-20240000949-A1 | Nucleic Acid-Derivatized Therapeutics | UNIV CHICAGO (US) | 2024-01-04 | — | — | US | disclosed |
| CN-116367849-A | Therapeutic agent derived from nucleic acid | 芝加哥大学 | 2023-06-30 | — | — | CN | disclosed |
| US-20230128322-A1 | SYK KINASE INHIBITORS AS TREATMENT FOR MALARIA | PURDUE RESEARCH FOUNDATION | 2023-04-27 | — | — | US | disclosed |
| WO-2006102898-A2 | OXAPROZIN OR A CLOSELY RELATED COMPOUND FOR THE TREATMENT OF ECZEMA | ASTION PHARMA A/S (DK) | 2006-10-05 | — | — | WO | disclosed |
| EP-1707201-A1 | Oxaprozin or a closely related compound for the treatment of eczema | Astion Development A/S (DK) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005102215-A1 | METHODS OF TREATMENT WITH SYK INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| US-20050232969-A1 | Methods of treatment with Syk inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128322-A1 | SYK KINASE INHIBITORS AS TREATMENT FOR MALARIA | SYK, BTK, MERTK | PARP1 1177/4885CSNK1A1 811/4885DYRK1B 226/4885 |
| US-20140309233-A1 | SYK KINASE INHIBITORS AS TREATMENT FOR MALARIA | SYK, BTK, MERTK | PARP1 1177/4885CSNK1A1 811/4885DYRK1B 226/4885 |
| US-20240122927-A1 | METHODS FOR TREATING HEMOLYTIC DISEASES AND SICKLE CELL DISEASE | SYK, BTK, CD47 | PARP1 2247/4885CSNK1A1 2036/4885DYRK1B 157/4885 |
| US-20230018687-A1 | METHODS FOR TREATING HEMOLYTIC DISEASES AND SICKLE CELL DISEASE | SYK, BTK, CD47 | PARP1 2247/4885CSNK1A1 2036/4885DYRK1B 157/4885 |
| US-20240000949-A1 | Nucleic Acid-Derivatized Therapeutics | NSUN2, NSUN3, POLRMT | PARP1 165/4885CSNK1A1 1827/4885DYRK1B 2634/4885 |
| US-20200345737-A1 | SYK KINASE INHIBITORS AS TREATMENT FOR MALARIA | SYK, BTK, MERTK | PARP1 1177/4885CSNK1A1 811/4885DYRK1B 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.